• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

OC-12: Stroke and risk of cancer: a Danish population-based cohort study
Source: Thrombosis Research - May 1, 2022 Category: Hematology Authors: N. Skajaa, K. Veres, F.S. Troelsen, J.D. Petersen, K. Adelborg, H.T. S ørensen Tags: Oral Communications Source Type: research

Therapeutic efficacy of heparin and direct factor Xa inhibitors in cancer-associated cryptogenic ischemic stroke with venous thromboembolism
Anticoagulation therapy, especially using heparin or recently developed oral direct factor Xa inhibitors (DiXals), is recommended as first-line treatment for cancer-related venous thromboembolism (VTE). However, the preventive efficacy of these anticoagulants for cancer-associated ischemic stroke is still unknown. We retrospectively investigated the efficacy of subcutaneous unfractionated heparin (UFH) and DiXals for preventing the recurrence of cancer-associated cryptogenic ischemic stroke with VTE.
Source: Thrombosis Research - August 23, 2021 Category: Hematology Authors: Genpei Yamaura, Takeshi Ito, Yosuke Miyaji, Naohisa Ueda, Yoshiharu Nakae, Takayuki Momoo, Tatsu Nakano, Yuji Johmura, Yuichi Higashiyama, Hideto Joki, Hiroshi Doi, Hideyuki Takeuchi, Tatsuya Takahashi, Shigeru Koyano, Shigeki Yamaguchi, Mutsumi Yokoyama, Source Type: research

Ischemic stroke in cancer patients treated with direct oral anticoagulants for venous thromboembolism
Direct oral anticoagulants (DOACs) are at least as efficacious as conventional anticoagulation therapy for the initial and long-term treatment of cancer patients with venous thromboembolism (VTE). Whether DOACs are non-inferior to low-molecular-weight heparin for the management of cancer patients with VTE is under investigation. In addition, the efficacy of DOACs for the treatment of cancer patients with arterial thrombosis (e.g., ischemic stroke) remains unclear. Herein, we report on two cancer patients admitted to our hospital with Stage IV gastric adenocarcinoma who were being treated with DOACs due to a history of VTE ...
Source: Thrombosis Research - March 31, 2017 Category: Hematology Authors: Yasufumi Gon, Manabu Sakaguchi, Junji Takasugi, Hideki Mochizuki Tags: Letter to the Editors-in-Chief Source Type: research

Cancer as a risk factor for stroke in atrial fibrillation patients receiving long-term oral anticoagulant therapy
cancer and cerebrovascular disease are among the most common causes of death in the developed countries and are both associated with a steep increase in incidence among the elderly population. Despite being a less frequent neurological complication in cancer patients, compared to metastases or neurotoxicity from anticancer treatment, stroke incidence in cancer patients is high [1]. The pathophysiology of stroke in cancer patients is largely unknown [2] and can be attributed to cardiac or non-cardiac embolism.
Source: Thrombosis Research - June 18, 2015 Category: Hematology Authors: Gentian Denas, Vittorio Pengo, Roberta Joppi, Paolo Prandoni Source Type: research

Time trends in pulmonary embolism: A matter of age and gender
Venous thromboembolism (VTE) is the third most common cardiovascular disease . Pulmonary embolism (PE) is potentially lethal and is the most serious manifestation of VTE . Notably, PE is the leading preventable cause of death in hospitalized patients , and is the third most common cardiovascular cause of death after myocardial infarction and stroke in Western world . Risk factors for VTE and PE include old age, surgery, immobilization, trauma, fractures, cancer, pregnancy, puerperium, oral contraceptive pill (OCP) use, and hormone replacement therapy (HRT) . Genetic factors are also important in VTE risk and family history...
Source: Thrombosis Research - June 24, 2013 Category: Hematology Authors: Bengt Zöller Tags: Editorials Source Type: research